Zentalis Pharmaceuticals (ZNTL) Receivables - Accured (2020 - 2026)

Zentalis Pharmaceuticals' Receivables - Accured history runs 7 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• On a quarterly basis, Receivables - Accured fell 23.27% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 23.27% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 34.49% from the prior year.
• Receivables - Accured grew to $2.1 million in Q1 2026 per ZNTL's latest filing, from $1.9 million in the prior quarter.
• Across five years, Receivables - Accured topped out at $3.3 million in Q4 2023 and bottomed at $266000.0 in Q1 2022.
• The 5-year median for Receivables - Accured is $2.1 million (2026), against an average of $1.9 million.
• Across the five-year window, Receivables - Accured jumped 719.48% in 2024 and tumbled 34.83% in 2025, its largest moves.
• Year by year, Receivables - Accured stood at $508000.0 in 2022, then surged by 556.89% to $3.3 million in 2023, then dropped by 11.81% to $2.9 million in 2024, then tumbled by 34.49% to $1.9 million in 2025, then rose by 8.97% to $2.1 million in 2026.
• Per Business Quant, the three latest ZNTL Receivables - Accured figures stand at $2.1 million (Q1 2026), $1.9 million (Q4 2025), and $2.2 million (Q3 2025).